StockData

Arcutis Biotherapeutics vs HUTCHMED (China)

ARQT and HCM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARQT and HCM compare

Arcutis Biotherapeutics grew revenue faster over the last twelve months (76.1% versus −13.0% for HUTCHMED (China)).

HUTCHMED (China) keeps more of each dollar of sales as profit, with a net margin of 83.3% compared with 6.1% at Arcutis Biotherapeutics.

Arcutis Biotherapeutics scores higher on the StockData Score (11 against 5 for HUTCHMED (China)), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARQTHCM
Size and price
Market cap$3.4B–
Share price$27.15$14.73
Change, 1 year18.8%−3.0%
Change, 5 years62.9%−58.1%
Beta (5Y)1.170.72
Employees354109
StockData Score
Total score11 (better)5
Valuation score00
Growth score4 (better)0
Performance score4 (better)3
Health score3 (better)2
Dividend score00
Valuation
P/E123×–
P/S7.4×–
P/B15.5×–
EV/EBITDA95.8×–
P/FCF87.2×–
FCF yield1.1%–
Fair value$5.46–
Margin of safety−397%–
Growth
Revenue growth (TTM)76.1% (better)−13.0%
Revenue growth, 5Y average–19.2%
Net income growth (TTM)–1111%
EPS growth (TTM)–1200%
Profitability
Gross margin91.1% (better)38.7%
Operating margin7.4% (better)−7.1%
Net margin6.1%83.3% (better)
FCF margin8.4% (better)−14.4%
Return on equity15.9%36.7% (better)
Return on invested capital36.9%–
Financial health
Debt / equity0.490.09 (better)
Net debt / EBITDA−3.79–
Interest coverage2.5× (better)−13.7×
Current ratio2.925.64 (better)
Altman Z-score6.33–
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions105%0.51%
Held by insiders9.3%0.44%
Insider net buying, 12 months−$11.1M–
Short interest, % of float15.9%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.